PT - JOURNAL ARTICLE AU - Leon Sobesky AU - Lukas Goede AU - Vincent J.J. Odekerken AU - Qiang Wang AU - Ningfei Li AU - Bassam Al-Fatly AU - Martin Reich AU - Jens Volkmann AU - Rob M.A. de Bie AU - Andrea A. Kühn AU - Andreas Horn TI - Effective subthalamic and pallidal deep brain stimulation – are we modulating the same network? AID - 10.1101/2021.02.02.21250817 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.02.21250817 4099 - http://medrxiv.org/content/early/2021/02/03/2021.02.02.21250817.short 4100 - http://medrxiv.org/content/early/2021/02/03/2021.02.02.21250817.full AB - The subthalamic nucleus and internal pallidum are main target sites for deep brain stimulation in Parkinson’s disease. Multiple trials that investigated subthalamic versus pallidal stimulation were unable to settle on a definitive optimal target between the two. One reason could be that the effect is mediated via a common network. To test this hypothesis, we calculated connectivity profiles seeding from deep brain stimulation electrodes in 94 patients that underwent subthalamic treatment and 28 patients with pallidal treatment based on a normative connectome atlas calculated from 1,000 healthy subjects. In each cohort, we calculated connectivity profiles that were associated with optimal clinical improvements. The two maps showed striking similarity and were able to cross-predict outcomes in the respective other cohort (R = 0.38 at p < 0.001 & R = 0.35 at p = 0.027). Next, we calculated an agreement map which retained regions common of both target sites. Crucially, this map was able to explain an additional amount of variance in clinical improvements of either cohort when compared to the maps calculated on the two cohorts alone. Finally, we tested profiles and predictive utility of connectivity maps calculated from different motor symptom subscores with a specific focus on bradykinesia and rigidity. While our study is based on retrospective data and indirect connectivity metrics, it delivers empirical data to support the hypothesis of a largely overlapping network associated with effective deep brain stimulation in Parkinson’s disease irrespective of the specific target.Competing Interest StatementM.R., and J.Vol. have business relationships with Medtronic, Abbott, and Boston Scientific, which are makers of DBS devices, but none is related to the current work. A.A.K. reports personal fees and non-financial support from Medtronic, personal fees from Boston Scientific, grants and personal fees from Abbott outside the submitted work. A.H. reports lecture fees for Medtronic and Boston Scientific and is a consultant for AlphaOmega. L.S., V.O., Q.W., N.L., B.A-F., LL.G., and R.d.B. have nothing to disclose.Funding StatementThis work was supported by the German Research Foundation (Deutsche Forschungsgemeinschaft, Emmy Noether Stipend 410169619 to A.H. and SPP 0141 to A.A.K.). The study was further funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Project-ID 424778381 TRR 295. The work was further supported by the EU Joint Programme Neurodegenerative Disease Research (JPND) & Deutsches Zentrum fuer Luft- und Raumfahrt, grant number JPND2020-568-008.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical vote obtained 31.10.2018 Order Number: EA2/186/18 Ethical committee Campus Charite Virchow, Universitaetsklinik Berlin Chair: PD Dr. E. Kaschina Management Board: Dr. med. K. Orzechowski Ethikkommission{at}charite.de http://ethikkommission.charite.de Chariteplatz 1, 10117 Berlin Ethical approval was given to Dr. Andreas Horn.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe DBS MRI datasets generated during and analyzed during the current study are not publicly available due to data privacy regulations of patient data but are available from the corresponding author upon reasonable request. All code used to analyze the dataset is openly available within Lead-DBS/-Connectome software (https://github.com/leaddbs/leaddbs). https://github.com/leaddbs/leaddbs STNsubthalamic nucleusGPiinternal globus pallidusDBSdeep brain stimulation